How does digoxin therapy influence hospitalizations and mortality in heart failure?

How does digoxin therapy influence hospitalizations and mortality in heart failure?

• A. It reduces symptoms and hospitalizations in some patients but does not conclusively reduce mortality; monitor for toxicity
• B. It cures HF
• C. It eliminates need for diuretics
• D. It worsens hospitalizations

Answer: (A)

Digoxin in heart failure helps by increasing the heart’s pumping force and, in some patients, by slowing the heart rate to improve filling. This tends to relieve symptoms and can reduce the frequency of decompensation episodes that lead to hospital admissions, especially in patients who remain symptomatic despite optimal standard therapy or who have atrial fibrillation with rapid rates. However, it does not have a proven, consistent mortality benefit in the overall heart failure population. The major trials showed reassuring effects on symptoms and hospitalizations but no clear reduction in death across groups, so it’s considered an adjunctive therapy rather than a life-prolonging treatment. Because digoxin has a narrow therapeutic window and interacts with many drugs and electrolyte states, careful monitoring is essential. Start with a low dose and adjust based on kidney function and serum levels, watching for signs of toxicity such as nausea, vision changes, confusion, or abnormal heart rhythms. Correct electrolytes (notably potassium), be mindful of interactions with medications like amiodarone or certain calcium-channel blockers, and reassess regularly to balance symptom relief with safety.

Digoxin in heart failure helps by increasing the heart’s pumping force and, in some patients, by slowing the heart rate to improve filling. This tends to relieve symptoms and can reduce the frequency of decompensation episodes that lead to hospital admissions, especially in patients who remain symptomatic despite optimal standard therapy or who have atrial fibrillation with rapid rates.

However, it does not have a proven, consistent mortality benefit in the overall heart failure population. The major trials showed reassuring effects on symptoms and hospitalizations but no clear reduction in death across groups, so it’s considered an adjunctive therapy rather than a life-prolonging treatment.

Because digoxin has a narrow therapeutic window and interacts with many drugs and electrolyte states, careful monitoring is essential. Start with a low dose and adjust based on kidney function and serum levels, watching for signs of toxicity such as nausea, vision changes, confusion, or abnormal heart rhythms. Correct electrolytes (notably potassium), be mindful of interactions with medications like amiodarone or certain calcium-channel blockers, and reassess regularly to balance symptom relief with safety.